Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011

Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011
Kewal Handa Of Pfizer & Aditi Kare Of Indoco Are Business Leaders While Pfizer, Abbott, GSK, Microlabs, Elder Pharmaceuticals, Fortis, Bharat Biotech, Adriot Are Biomed Among Those Win The Race In Important Categories.
Mumbai : 16th December 2011 : 4th Annual Pharmaceutical Leadership Summit & Awards 2011 ( www.pharmasummit,in ) organized by India’s leading bi-monthly Pharma Magazine ( www.pharmaleaders.co.in ) & IACC culminated in high notes as 23 categories of various Nominations were declared Winners in a sequel to 60 days of votings & Juries final verdict. Among those Companies & Individuals who were declared Winners for their outstanding performance in fiercely competitive India Pharma Market are 1.Business Leader of the Year 2011 : Mr KewalHanda, Managing Director, Pfizer India Ltd. 2.Business Woman of the Year 2011 ( Gen-Next Pharma Leader), MrsAditi Kare Panandikar, Whole Time Director, Indoco Remedies Ltd. 3.Dynamic Entrepreneur of the Year 2011: Dr Krishna Ella, CMD, Bharat Biotech International Ltd. 4.Pharma OTC Company of the Year 2011: Ranbaxy Global Consumer Healthcare. 5.India’s Most Admired Nutrition &Neutraceuticals of the Year 2011, Revital Woman & Abbott Healthcare Pvt Ltd. 6.Company of the Year 2011: Venus Remedies Ltd.7.Pharma CSR Organisation of the Year 2011: Ranbaxy Labs Ltd. 8.Pharma Professional Of the Decade 1.Dr Ajit.V.Dangi, CEO & President, Danseen Consulting. 2. Mr RanjitShahani, Vice-Chairman & MD, Novartis India Ltd,3. Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. 9.Brand of the Year 2011: Revital&Volini. 10.Innovative R & D Company of the Year 2011, Bharat Biotech International Ltd. 11.Emerging Brand of The Year :B-COLEN RANGE of Galpha Labs. 12.India’s Most Admired Foundation in Social Innovation: Right to Vision Programme of Wockhardt Foundation. 13.Pharma Achiever of the year in SME,Dr. Rege's Laboratories.14.India’s Most Admired Company in Blood and Biological Products 2011,Synergy Diagnostics Pvt Ltd. 15.India's Most Admired Pharma Company 2011: Microlabs Ltd. 16.India's Most Watched Company of the Year 2011, Elder Pharmaceuticals Ltd,17. Emerging Company of the Year 2011,AanjaneyaLifecare Ltd. 18.India’s Most Admired Company in Exports 2011:Genom Biotech Pvt Ltd. 19.Research Scientist of the Year 2011: Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 20.Multinational Company of The Year 2011. ( Joint Winners)1. Pfizer India Ltd, 2. Glaxo SmithKline Pharmaceuticals Ltd.21.India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. 22.Biotech Research Company of The Year 2011. Adroit Biomed Ltd.23.India’s Most technically & scientifically advanced Pharmaceutical Manufacturing unit of the year 2011. Aanjaneya Lifecare Ltd.
Speaking on the Award Declarations, Mr Satya Brahma, Chairman of Network 7 Media Group said “ Pharmaleaders salute these shining stars who bagged these coveted Awards by a rare display of achievements & performed under a changed healthcare scenario”.
With an aptly theme of Generation Next Indian Pharma Leaders, Billionaire Minds, Drivers for Growth at 4th Annual Pharmaceutical Leadership Summit & Awards 2011, veterans of the India’s Healthcare Industry debated on many topics that grappled Indian Healthcare segments. In an opening address, Mr Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders Magazine ( www.pharmaleaders.co.in ) said “ Indian Healthcare Industry has emerged out as a global super Power & has displayed remarkable display of manufacturing excellence & quality medicines & is way ahead of many developed nations, it is only a matter of time that it will overtake China in coming days, he added. He also lamented at Policy Makers & Authorities for slow decision making process specially in the context of Draft Pricing Policy & FDI in Healthcare Sector & urged the Ministry to hear the voices of the healthcare industry”.
Amonth those who addressed at Asia’s Biggest Leadership Meet are Mr. S. Krishnakumar (KK), Market Leader ( Life Sciences)Future Steps ( A Korn/Ferry Company, Dr Lalit S Kanodia, President Indo-American Chamber of Commerce, (IACC), Western Region, & CMD, Datamatics Ltd. Should drug prices be regulated?Mr. Kewal Kanda, MD, Pfizer India Ltd.` India – An Emerging Pharmaceutical Powerhouse , Dr Ajit V Dangi, Board Chairman, Fulford India Ltd. President & CEO, Danseen Consulting. Dr. Rashmi Barbhaiya , CEO and Managing Director - Advinus Therapeutics Ltd “From Scientist To CEO. The vision: Create a Pharmaceutical company focused on discovering and developing the next generation of high end commercialized medicines.Recent Advancements in Blood & Biological products :Mr Sanjay Bawsay, Managing Director, Synergy Diagnostics Pvt Ltd. Human biotechnology research in India, with emphasis on the BBIL story.Mr. Sai D Prasad, Project Manager - Rotavirus Vaccine Project and Vice President - Business Development. Are FDI & Price Control Policy in Indian Pharma Sector deterrent for growth & Globalize Indian Healthcare Industry. Mr. Shashikant B. Shinde ,Whole Time Director, AanjaneyaLifecare Ltd. Differentiate or Die - Pharmaceutical Industry in India. Mr.DeepakNaik, Managing Director Health 'N' U Therapeutics Pvt. Ltd. MrAnand Desai, National President, IACC & Managing Partner, DSK Legal : Do Pharmaceutical Companies Have Debt Crisis Strategy?. A Legal Perspective. Mr Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. Moving Beyond the Healthcare Debate : The Transformative Trends That Will REALLY Define Our Future. Pharma’s Value Proposition - How The Industry Must Change. Perspectives On Current Industry Challenges .Mr. Sunil Madhok, Director, Business Development, Pfizer India Ltd.
More details of the post event are available on requests at editor.in.chief@pharmaleaders.co.in .

Watch Pfizer Chief Kewal Handa As He Speaks On His Perspectives of The Controversial Draft Pharma Pricing Policy

Indian Healthcare Industry’s leading voice & one of the most respected name in the pharmaceutical sector, Mr Kewal Handa who strategies world’s leading drugmaker Pfizer in Indian operation will be speaking exclusively via televised tape on how The Centre’s decision to decontrol drug prices would take essential medicines beyond the reach of the common citizen. The controversial policy has been a bone of contention in the industry as there are no takers as the key pharma firms flay ‘populist' draft policy. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank.Patented drugs are not defined in the drugs (Price Control) Order, 1995 (DPCO, 1995). Under the provisions of the DPCO, 1995, prices of 74 scheduled bulk drugs and the formulations containing any of these scheduled drugs are controlled. National Pharmaceutical Pricing Authority (NPPA) fixes or revises prices of scheduled drugs / formulations as per the provisions of the DPCO, 1995. Anti-cancer medicines are non-scheduled drugs, i.e. not covered under DPCO, 1995. In respect of non-scheduled drugs, manufacturers are at liberty to fix the prices by themselves without seeking the approval of Government / NPPA. Department of Pharmaceuticals has prepared a draft National Pharmaceutical Pricing Policy 2011 (NPPP-2011) based on the criteria of essentiality and requirements as stipulated by the Ministry of Health & Family Welfare. The draft Policy envisages bringing the National List of Essential Medicines (NLEM) – 2011 and associated medicines under price control. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank. This information was given by the Minister of State for Chemicals and Fertilisers, Srikant Kumar Jena in a written reply in the Lok Sabha recently.
Handa speaks exclusively at the 4th Annual Pharmaceutical Leadership Summit 2011(www.pharmasummit.in ) organised by Pharmaleaders ( www.pharmaleaders.co.in ) to be held in Mumbai ob 10th December 2011 via Careworld TV. Mr Handa has strong reservations on the proposed policy as he feels that this will have detrimental effect on the healthcare sector. Kewal Handa is Managing Director, Pfizer Limited, the world’s No.1 pharmaceutical company that discovers and develops break-through drugs, provides information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer products; and is a global leader in corporate responsibility. Under his leadership, the company is now aggressive in its growth plans and has launched several new products.
Kewal is a reputed industry expert who takes the lead on key issues that concern the pharmaceutical sector. As Vice President of the Organisation of Pharmaceutical Producers of India (OPPI), he has been at the forefront of the industry’s efforts to resolve issues pertaining to the pharmaceutical sector. He is also the Chairman of DPCO & Taxation Committee of OPPI. He has recently been appointed as the President of All India Management Association and is a committee member of various industry bodies in the country. Kewal was awarded the ‘India CFO 2004 – Excellence in Finance in an MNC’ by International Market – Assessment Group and has recently won the Bharat Shiromani Award. A qualified Management Accountant and Company Secretary, and with a Masters Degree in Commerce from Sydenham College, Mumbai, Kewal has completed the Pfizer Leadership Development Program from Harvard University, the Senior Management Development Program from IIM, Ahmedabad. He has also done a course on Marketing Strategy from Columbia Business School. Mr. Handa is also the Managing Director of Wyeth Ltd.